Cue Biopharma (CUE) Stock
What Cue Biopharma's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -44.7x
- Revenue growth
- +354.4%
- Operating margin
- -262.0%
What Cue Biopharma's price implies
Cue Biopharma's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Cue Biopharma's 10-K filings.
Cue Biopharma revenue and free cash flow
FY2017–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $15M | $1M | $5M | $9M | $27M |
| Net income | -$44M | -$53M | -$51M | -$41M | -$27M |
| Free cash flow | -$40M | -$42M | -$40M | -$36M | -$22M |
| EPS (diluted) | -$42.30 | -$44.70 | -$33.30 | -$21.60 | -$8.40 |
| Operating margin | -292.6% | -4,275.1% | -949.9% | -446.9% | -96.7% |
Superinvestors who own CUE
From each investor's latest 13F filing (what a 13F shows). All 2 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Didric Cederholm Lion Point Capital | Trimmed | $2M | 8.0% | Q2 2026 |
| Jim Simons Renaissance Technologies | Trimmed | $463,585 | 0.00% | Q2 2026 |
Cue Biopharma insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you). Every purchase
No open-market insider purchases of CUE in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from CUE's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Cue Biopharma compares
Cue Biopharma's revenue growth is higher than 96% of Healthcare companies and 98% of the 3,494 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 96% | 98% |
| Operating margin | 15% | 5% |
| ROE | 0% | 0% |
Questions about Cue Biopharma
Are Cue Biopharma insiders buying the stock?
No open-market insider purchases of CUE in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Cue Biopharma?
2 of the superinvestors Investingly tracks hold CUE in their latest 13F, including Didric Cederholm, Jim Simons.
Companies like Cue Biopharma
Nkarta, Inc. (NKTX)$105MUnicycive Therapeutics, Inc. (UNCY)$103MVivani Medical, Inc. (VANI)$102MImmunic Inc (IMUX)$107MAnixa Biosciences Inc (ANIX)$108MNRX Pharmaceuticals, Inc. (NRXP)$101MNovaBridge Biosciences (NBP)$100MAnavex Life Sciences Corp (AVXL)$111MCellectis SA (CLLS)$112M All Healthcare stocks→Prices and ratios as of Nov 10, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.